MedTrace Logo

A Phase I Clinical Trial of BAT5906 Injection in Patients With Wet Age-related Macular Degeneration

NCT04151212 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-09-23

No results posted yet for this study

Summary

A Phase I Clinical Trial for BAT5906(single-dose;for injection) on Safety and Pharmacokinetics for Patients with Age-related macular degeneration.

Conditions

  • Age-related Macular Degeneration

Interventions

DRUG

BAT5906 injection

Signal dose escalation starting from 0.3mg. Route of administration: intravitreal injection

Sponsors & Collaborators

Principal Investigators

  • Youxin Chen · Peking Union Medical College

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-30
Primary Completion
2021-02-28
Completion
2021-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04151212 on ClinicalTrials.gov